GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Total Stockholders Equity

10x Genomics (10x Genomics) Total Stockholders Equity

: $741.0 Mil (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

10x Genomics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $741.0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. 10x Genomics's Book Value per Share for the quarter that ended in Dec. 2023 was $6.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. 10x Genomics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.13.


10x Genomics Total Stockholders Equity Historical Data

The historical data trend for 10x Genomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Premium Member Only Premium Member Only 420.08 739.07 817.57 805.74 741.04

10x Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 805.74 802.39 793.30 745.22 741.04

10x Genomics  (NAS:TXG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

10x Genomics's Book Value per Share for the quarter that ended in Dec. 2023 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

10x Genomics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


10x Genomics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics (10x Genomics) Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006